

CO:IRD:2026:27:66

Date: 04.06.2026

<b>National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C/1, 'G' Block, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051 <b>Scrip code – CENTRALBK</b>	<b>BSE Limited</b> Corporate Relationship Dept., Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400001 <b>Scrip Code – 532885</b>
--	---

Dear Sir/Madam,

**Sub: Newspaper Publication regarding Notice for Election of One Shareholder Director on the Board of Bank.**

With reference to above, please find the enclosed copy of extract of newspaper advertisements regarding Notice to Shareholder of Bank for Election of One Shareholder Director on the Board of Bank in the 19<sup>th</sup> Annual General Meeting of the Bank scheduled on Friday, 17<sup>th</sup> July 2026 published in following newspapers on 04<sup>th</sup> June, 2026.

<b>Name of Newspaper</b>	<b>Editions</b>
Business Standard	English - All Editions
Business Standard	Hindi - All Editions
Navarashtra	Marathi Edition

Please take the above on your record in compliance with Regulation 47 of SEBI (LODR) Regulations, 2015.

Thanking you.

Yours faithfully,

For **CENTRAL BANK OF INDIA**

**CHANDRAKANT BHAGWAT**  
Company Secretary & Compliance Officer

Encl.: As above

# India biz, new launches healthy for Zydus Life


Brokerages remain positive, raise FY27 estimates for the firm

RAM PRASAD SAHU  
Mumbai, 3 June

The Zydus Lifesciences stock has gained 20 per cent over the last month, and has been the best-performing pharma stock over the past three months. The gains for the pharma major are on the back of an expanding specialty portfolio, strong India business growth, robust product pipeline, and value-accretive acquisitions. While the stock has run up sharply (trading at ₹1,076) and has outperformed peers, some brokerages are positive on its outlook and have raised their estimates for 2026-27 (FY27).

The near-term triggers are the recent acquisitions and the results for the fourth quarter of 2025-26 (Q4FY26). Powered by growth across key business segments, the company delivered a revenue uptick of 18 per cent year-on-year (Y-o-Y) and 9.6 per cent quarter-on-quarter (Q-o-Q). The revenue showing was above estimates given the performance in North America (on a sequential basis), which was aided by market share gains in Mirabegron, strong traction in new launches (especially generic version of Protracta), and seasonal factors.

Among the growth drivers were Indian formulations, which reported a sales growth of 14 per cent Y-o-Y, while the Indian consumer business too was strong at 52.8 per cent growth. Growth momentum in the Indian formulation segment was led by chronic therapies coupled with contribution from recent biosimilar launches, including Tishtha (nivolumab), Anyra (afilbercept), and semaglutide brands. The consumer segment growth was on account of the acquisition of UK-based digital health platform Comfort Click. The India business accounts for 43 per cent of consolidated revenues. While the company received a Warning Letter for its Baddi site it was in response to a request for records and does not pertain to any



## Positive signs

onsite inspection of the facility by the USFDA. The company said that it will not impact current operations and supplies from the Baddi site.

The margin performance was a mixed bag. Gross margins came in at 73.4 per cent, up marginally, while operating profit margins decreased 800 basis points (bps) Y-o-Y. While on a sequential basis margins were up 110 bps, the Y-o-Y decline was on account of lower contribution from the generic version of revlimid. Research and development (R&D) expenses were 45.5 per cent higher Y-o-Y and accounted for 9.2 per cent of revenue. Other expenses, excluding R&D, too were up 45 per cent Y-o-Y and 8 per cent Q-o-Q given new business consolidation. The expansion of gross and operating profit margins on a sequential basis was on account of better product mix, favourable currency, and operating leverage, pointed out Saion Mukherjee and Kushal Chovatia of Nomura Research. The brokerage has a "buy" rating, with a target price of ₹1,140 based on 30 times its FY27 earnings.

Motilal Oswal Research has raised its earnings estimates by 4-5 per cent for FY27 and FY28, factoring

in increased traction in limited-competition products in the US, industry-beating performance in domestic formulations and other emerging markets, higher R&D spending, and enhanced efforts toward marketing/promotion. The brokerage has a "neutral" rating on the stock, and a target price of ₹1,080.

Going ahead, the company expects the India formulations business to outperform the pharma market by 200-400 bps. Further, it expects Zydus Wellness to report double-digit growth, excluding the impact of acquisitions. The North American segment could witness revenue growth in single digits on a large base, with product-specific opportunities in the second half (H2) of FY27. While overall revenue growth is expected to be in high teens, operating profit margin target is upwards of 24 per cent.

The key catalysts for the stock, according to analysts led by Vishal Manchanda of Systematic Research, going forward are approval for saroglitazar by the USFDA in Q4FY27, and launch of the generic version of pabociclib (under 180 days exclusivity) in the same quarter.



# Late in retirement savings at 40? Act now

SANJAY KUMAR SINGH & KARTHIK JEROME

Ritu Arora (name changed on request), who works at a publishing house in Delhi, recently turned 40. A conversation with a senior citizen neighbour, who described his growing difficulty in coping with inflation and rising health-care expenses, made her realise with a jolt that she had not begun saving for retirement, apart from the mandatory deduction for the Employees' Provident Fund (EPF). A recent survey by Finance 1 found that 75.5 per cent of respondents nearing retirement did not have a detailed retirement plan.

## Low on priority list

"Present bias" often makes near-term expenses appear more urgent than retirement. "Retirement falls in the category of important but not urgent goals. The benefits are visible only after a long period of time, while shorter-term goals demand immediate attention," says Vishal Dhawan, founder and chief executive officer, Plan Ahead Wealth Advisors.

"Many salaried individuals

assume future salary growth will compensate for delayed savings," says Arvind Rao, founder, Arvind Rao and Associates.

Some fail to recognise that longer life expectancy has made retirement planning more important now. "Many underestimate the impact of inflation on future expenses," says Arnab Pandya, founder, Moneyeduschool.

## Delay raises savings burden

Suppose that a person sets a target corpus of ₹5 crore. Assuming an annual return of 10 per cent, one who starts at 25 needs to save about ₹15,500 a month. One who starts at 40 needs to save almost ₹73,000 a month. "The required monthly saving becomes nearly five times higher due to the 15-year delay," says Rao.

## Estimate the corpus

A 40-year-old should begin by calculating current annual expenses. Next, identify expenses that may not continue after retirement. Also identify expenses that may rise after retirement, especially health-care and leisure related. "A safe estimate is that post-retirement expenses will be about 80 per cent

of current expenses," says Rao.

"Target a retirement corpus equal to 30-35 times annual expenses," says Dhawan.

Another way to estimate the required corpus is to use the 4 per cent withdrawal rule. "This rule assumes that annual withdrawals should not exceed 4 per cent of the corpus," says Rao. If annual retirement expense at age 60 is ₹30.8 lakh (applying 6 per cent inflation over 20 years to ₹9.6 lakh current expense), the base corpus required would be around ₹7.7 crore.

## Use right product mix

A 40-year-old should not invest too conservatively. Equity mutual funds should be a key investment vehicle as the portfolio still has a 20-year horizon to grow. They tend to beat inflation over long periods. But investors must be

## Cost of delaying investments

A 15-year delay, from age 25 to age 40, reduces the final corpus by about 85 per cent across these monthly investment amounts

Monthly investment (₹)	Corpus at 60	If started at 25	If started at 40
10,000	6.43	0.98	
15,000	9.64	1.48	
20,000	12.86	1.97	
25,000	16.07	2.47	

Assumption is that monthly investment grows at 12% per annum until age 60. Source: Moneyeduschool

able to tolerate volatility.

Another product that can be used is the National Pension System (NPS). NPS offers additional tax benefit of ₹50,000. "Under the new tax regime, salaried individuals can invest up to 14 per cent of basic salary through NPS and qualify for deduction," says Rao. It has a low fund management charge and allows equity allocation of up to 75 per cent. EPF returns (8.25 per cent) are higher than that of many other fixed-income instruments. "Employees with access to EPF should take full advantage of it and should not touch EPF money except in a life-or-death situation," says Renu Maheshwari, Sebi-registered investment advisor, cofounder and principal advisor, Finscholarz Wealth Managers. But EPF is available only to salaried employees.

Public Provident Fund (PPF) offers tax-free return of 7.1 per cent. It has a 15-year lock-in. One can, however, invest only up to ₹1.5 lakh per annum in PPF. PPF and EPF cannot provide growth impetus. "But they can provide stability and tax-free returns," says Pandya.

## Prioritise retirement

Late starters should identify how much their current retirement-linked assets can grow to by age 60 and compare that projected value with the target corpus. Once the gap is known, they should create an annual savings plan and try to step up their investments. "Avoid high-risk strategies such as F&O and short-term trading. Don't turn excessively conservative either," says Maheshwari.

# Unexpected money in your account? SBI warns of 'jumped deposit scam'

Receiving unexpected money in your bank account may seem harmless, but State Bank of India (SBI) says it could be the first step in a sophisticated UPI fraud designed to empty your account.

SBI recently advised customers against the "jumped deposit scam", where fraudsters transfer a small amount of money

into a victim's bank account and then contact them claiming the transfer was accidental.

## Modus operandi

A scammer transfers a small amount, often a few rupees or a few hundred rupees, into a person's bank account.

The victim then receives a phone call or message claiming

that the transfer was made by mistake.

Instead of asking the victim to send the money directly, the scammer sends a UPI "collect request" or payment approval request. Believing they are merely returning the accidental transfer, the victim approves the request.

The approved transaction can be for a significantly higher

amount than expected, resulting in financial loss.

## SBI's advice

- Avoid engaging with unknown callers who claim to have accidentally transferred funds
- Verify a transaction through their banking app or statement
- Avoid approving any "UPI collect" requests.

Read full report here: mybs.in/2g6qUEB

COMPILED BY AMIT KUMAR

**सेंट्रल बँक ऑफ इंडिया**  
**Central Bank of India**

09<sup>th</sup> Floor, Chandermukhi, Nariman Point, Mumbai 400021  
Tel. no. 022 66387575  
Email id: investors@centralbank.bank.in  
Website: www.centralbank.bank.in

**NOTICE TO SHAREHOLDERS OF THE BANK**

We wish to inform that the Board of Directors of Bank at their meeting held on 03<sup>rd</sup> June, 2026 has approved to conduct the Election of One Director from amongst Shareholders other than the Central Government pursuant to Section 9(3)(f) of the Banking Companies (Acquisition and Transfer of Undertakings) Act, 1970 read with Banking Regulations Act 1949, the Nationalized Bank (Management and Miscellaneous Provisions) 1970, Central Bank of India (Shares & Meetings) Regulations, 1998 as amended from time to time, RBI Master Directions dated: 28.11.2025 and SEBI (LODR) Regulations 2015 to fill in the vacancy of one Director for a period of 03 years w.e.f. 18<sup>th</sup> July, 2026 at the 19<sup>th</sup> Annual General Meeting (AGM) of the shareholders of the Bank to be held on Friday, 17<sup>th</sup> July, 2026 through Video Conferencing (VC)/Other Audio Visual Means (OAVM).

Accordingly, the Bank has fixed **Friday, 12<sup>th</sup> June, 2026** as the **Specified/ Cut-off date** for the purpose of ascertaining the shareholders of the Bank eligible to participate i.e. to Nominate, Contest and Vote in the aforesaid election process. The last date for Submission of Nominations forms is **Thursday, 2<sup>nd</sup> July, 2026**.

The Notice of 19<sup>th</sup> Annual General Meeting of Bank along with forms for Election will be made available on Bank's website at [www.centralbank.bank.in](http://www.centralbank.bank.in) in due course of time.

**Registration of e-mail addresses by the Members:**  
Member(s) holding shares in physical form and have not registered their e-mail addresses with the Bank, can register their e-mail address and can obtain soft copies of the Notice of the 19<sup>th</sup> AGM with Annual Report and/or login details for joining the AGM through VC/OAVM including voting, by submitting Form ISR-1 to the RTA along with relevant documents at MUFG Intime India Private Limited, C 101, 247 Park, LBS Marg, Vikhroli West, Mumbai 400083 Phone: 08108116767 or over e-mail to [mt.helpdesk@in.mpmis.mufg.com](mailto:mt.helpdesk@in.mpmis.mufg.com) on or before 12<sup>th</sup> June, 2026. The ISR forms can be downloaded from the website of the RTA at <https://web.in.mpmis.mufg.com/KYC-downloads.html>

Members holding shares in Demat mode can update their e-mail ID with their respective Depository Participant.

**For CENTRAL BANK OF INDIA (CHANDRAKANT BHAGWAT)**  
Date: 03<sup>rd</sup> June, 2026  
Company Secretary & Compliance Officer

**CHEMFAB ALKALIS LIMITED**  
CIN: L24290TN2009PLC071563

Regd. Office: Team House, GST Road, Vandalur, Chennai 600 048.  
Website: [www.chemfabalkalis.com](http://www.chemfabalkalis.com) Email: [ccalcosec@ccal.in](mailto:ccalcosec@ccal.in)  
Phone No: +91 44 22750323 Fax No: +91 44 22750860

**NOTICE**

Notice is hereby given that pursuant to SEBI Circular HO/38/13/11(2)2026-MIRSD POD/1/3750/2026 dated 30.01.2026 on the subject Ease of Doing Investment Special Window for Transfer and Dematerialisation of Physical Shares, a request has been received by the Company from Name of Proposed Transferee Ratanchand Sumerchand Bafna, residing at 8/1 Cenatoph Road 1<sup>st</sup> lane Teynampet Chennai 600018 to transfer the below mentioned securities held in the name(s) of the security holder(s) as detailed below, to his/her/their name(s). These securities were claimed to have been purchased by him / her / them and could not be transferred in his/her/their favour

The lost share certificate details are as below:

Folio Number	Name(s) of the Holder(s) and registered address	Security Type and face value	Number of Shares	Share Certificate Number	Distinctive Numbers	
					From	To
M0000042	M M GALADA, 8/1CENOTAPH, FIRST LANE, TEYNAMPET CHENNAI 600018	EQUITY 10rs	142	360	1045223	1045364
L0000080	LAXMI DEVI, 8/1CENOTAPH, FIRST LANE, TEYNAMPET CHENNAI 600018	EQUITY 10rs	142	351	1043124	1043265

Any person who has a claim in respect of the above mentioned securities, should lodge such claim / intimate objection, if any, to the proposed transfer with the Company at its Registered Office within 30 days from this date along with appropriate documentary evidence thereof in support of such claim / objection, else the Company will proceed to transfer the securities in favour of Ratanchand Sumerchand Bafna (Names of the Proposed Transferee(s)), without any further intimation.

**For Chemfab Alkalis Limited**  
Bharatraj Panchal  
Company Secretary and Compliance officer

Place : Chennai  
Date : 03.06.2026

**APOLLO HOSPITALS ENTERPRISE LIMITED**  
CIN: L85110TN1979PLC008035

Regd. Office : No. 19, Bishop Gardens, Raja Annamalaiapuram, Chennai - 600 028.  
Secretarial Dept : Ali Towers, III Floor, No. 55, Greems Road, Chennai - 600 006.  
Tel. No. 044-28290956, 28293896. Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)

**NOTICE OF LOSS OF SHARE CERTIFICATE**

Notice is hereby given that the following share certificate(s) issued by the Company registered in the name of the person(s) specified herein is/are reported to have been lost.

Folio No.	Registered holder	Share Certificate No.	Distinctive Number(s)		No. of Shares
			From	To	
825	BABY DAVIS	350825	3845227	3845426	200

The Company shall proceed to issue the duplicate share certificate in favour of shareholder / claimant in lieu of the original share certificate in the absence of any objection with evidence is lodged within 7 days of publication of this notice to the undersigned from any person claiming any interest, right or title to the shares specified above. The Company shall not entertain any claim there after. Any person dealing with the above-said shares will be doing so at his/her own risk.

**For Apollo Hospitals Enterprise Limited**  
S M Krishnan  
Sr. Vice President (Finance) & Company Secretary

Place : Chennai  
Date : June 03, 2026

**KANCO TEA & INDUSTRIES LIMITED**  
CIN: L15491WB1983PLC035793

Regd. Office: Jasmine Tower, 3rd Floor, 31 Shakespeare Sarani, Kolkata-700 017  
Website: [www.kanco.in](http://www.kanco.in), email id: [contact@kanco.in](mailto:contact@kanco.in)  
Telefax: (033) 2281 5217

**SPECIAL WINDOW FOR TRANSFER AND DEMATERIALISATION OF PHYSICAL SECURITIES**

Notice is hereby given to Shareholders that in terms of SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30<sup>th</sup>, 2026 the Special Window has been extended for a period of one year from February 05 2026 to February 04 2027, to facilitate re-lodgement of transfer requests of physical shares. This facility is available for transfer deeds that were lodged prior to April 01, 2019, but were rejected/returned/not attended due to deficiency in the documents/process or others.

All transfer requests duly ratified and re-lodged during the aforesaid period will be processed through transfer-cum-demat-mode i.e. the demat will be issued only in dematerialised form after transfer. The Lodger(s) must have a demat account and provide Client Master List (CML) along with the transfer document(s), Share certificate (s), and other necessary document(s) while lodging the documents for transfer with our Registrar and Share Transfer Agent (RTA). Eligible shareholders are requested to contact the Company's RTA i.e. MUFG Intime India Private Limited at their email ID: [investor.helpdesk@in.mpmis.mufg.com](mailto:investor.helpdesk@in.mpmis.mufg.com) or send the requisite documents at their office at Rasoi Court, 5th Floor, 20 R N. Mukherjee Road, Kolkata - 700001.

**SECOND 100 DAYS CAMPAIGN - "SAKSHAM NIVESHAK"**

Investors Education and Protection Fund Authority (IEPPA) has initiated the Second 100 Days Campaign - "Saksham Niveshak" from 1 April 2026 to 9<sup>th</sup> July 2026 to reach out to shareholders whose Dividend(s) has remained unpaid / unclaimed and whose Know Your Customers (KYC) other details have not been updated. In line with this, the shareholders of the Company having unpaid / unclaimed dividend(s) or whose KYC details have not been updated are requested to reach out to the Company's RTA at the address as given above.

Sd/  
Charulata Kabra  
Company Secretary & Compliance Officer

Place: Kolkata  
Date: 4th June, 2026

**PPAP AUTOMOTIVE LIMITED**  
CIN: L74899DL1995PLC073281

Registered Office: 54, Okhla Industrial Estate, Phase-III, New Delhi-110020  
Tel: +91-11- 65260001  
Website: [www.ppapco.in](http://www.ppapco.in), E-mail ID: [investorservice@ppapco.com](mailto:investorservice@ppapco.com)

**NOTICE TO THE SHAREHOLDERS OF THE COMPANY**

**SPECIAL WINDOW FOR RE-LODGE/MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES**

In accordance with the SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026, all shareholders are hereby informed that another special window has been opened for a period of one year from February 05, 2026 to February 04, 2027, for transfer-cum-dematerialization of physical securities, which were sold/purchased prior to April 01, 2019.

Shareholders whose transfer deeds were lodged prior to April 01, 2019 and were rejected/returned/not attended to due to deficiency in documents or process, or those who had not lodged the transfer earlier, may submit the necessary documents as mentioned in the aforesaid Circular to Company's RTA, MUFG Intime India Pvt. Ltd. (Formerly Link Intime India Pvt. Ltd.) having office at Noble Heights, 1st Floor, Plot No. NH 2, LSC, C-1 Block, Near Savitri Market, Janakpuri, New Delhi-110058, helpline no. +91 11 49411000. A shareholder may raise a service request at [https://web.in.mpmis.mufg.com/helpdesk/service\\_Request.html](https://web.in.mpmis.mufg.com/helpdesk/service_Request.html), or send an email at [investor.helpdesk@in.mpmis.mufg.com](mailto:investor.helpdesk@in.mpmis.mufg.com).

The Securities so transferred shall be mandatorily credited only in dematerialized mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien marked/pledged during the said lock-in period.

For clarity with regard to applicability of this window, the matrix below may be referred to:

Execution Date of Transfer Deed	Lodged for transfer before April 01, 2019?	Original Security Certificate Available?	Eligible under Current Window
Before April 01, 2019	No (Fresh lodgement)	Yes	✓
Before April 01, 2019	Yes (Rejected/Returned earlier)	Yes	✓
Before April 01, 2019	Yes	No	X
Before April 01, 2019	No	No	X

Further, the following cases will not be considered under the window for processing:  
1. Cases involving disputes between transferor and transferee  
2. Shares which have been transferred to Investor Education and Protection Fund ("IEPF")

**Note:** All the shareholders are requested to update their KYC Details with Company/RTA/Depository Participants.

**For PPAP Automotive Limited**  
Sd/  
Pankhuri Agarwal  
Company Secretary & Compliance officer

Place : New Delhi  
Date : 03 June, 2026

**CARBORUNDUM UNIVERSAL LIMITED**  
CIN: L29224TN1954PLC000318

Registered Office: 'Dare House', No. 234, N.S.C. Bose Road, Parnys, Chennai-600 001. Tel: +91-44-30006161  
Email: [investorservices@cumu.murugappa.com](mailto:investorservices@cumu.murugappa.com) Website: [www.cumu-murugappa.com](http://www.cumu-murugappa.com)

**NOTICE TO MEMBERS**

Notice is hereby given pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ('Rules') notified by the Ministry of Corporate Affairs.

As per section 124(6) of the Companies Act, 2013 ('the Act') and the above mentioned Rules, all shares in respect of which dividends has not been paid or claimed for seven consecutive years or more are required to be transferred to the Demat Account of the Investor Education Protection Fund ("IEPF") Authority. In respect of the Final Dividend declared for the financial year 2018-19, the due date for transfer of shares as per the Act/Rules is **6<sup>th</sup> September 2026**. Adhering to the various requirements set out in the Rules, the Company has communicated individually to the concerned shareholders whose shares are required to be transferred to IEPF Authority under the said Rules at their latest available address.

The Company has uploaded full details of such shareholders and shares due for transfer to IEPF Authority on its website <https://www.cumu-murugappa.com> for verification by the concerned shareholders. Shareholders may note that both unclaimed dividends and the shares to be transferred to the IEPF Authority including all benefits accruing on such shares, if any, can be claimed by them from the IEPF Authority after following the due procedure prescribed in the Rules.

In case the Company does not receive the requisite documents by **17<sup>th</sup> August 2026**, the Company shall, with a view to comply with the requirements of the said Rules, transfer the shares to the IEPF Authority as per procedure stipulated therein without any further notice.

Shareholders having any query in this regard may contact the Company's Registrar and Share Transfer Agent or the Company as mentioned herein below:

<b>Carborundum Universal Limited</b> 'Dare House', 234, N.S.C. Bose Road, Parnys, Chennai 600 001. Tel: +91-44-30006166 Email: <a href="mailto:investorservices@cumu.murugappa.com">investorservices@cumu.murugappa.com</a> Contact Person: Ms. Jolly H Jivani, Investor Relationship Officer.	<b>Kfin Technologies Limited</b> Unit: Carborundum Universal Limited Selenium Building, Tower B, Plot 31 & 32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad - 500 032. Tel No: 040-6716222/1527 Toll Free No.: 1800-3094-007 Email: <a href="mailto:einwardr@kfintech.com">einwardr@kfintech.com</a> Contact Person: Mr. S R Ramesh, Deputy Vice President
--	---

**For Carborundum Universal Limited**  
Sd/  
Rekha Surendhiran  
Company Secretary

Place : Chennai  
Date : 3<sup>rd</sup> June 2026

**MAHINDRA MANULIFE INVESTMENT MANAGEMENT PRIVATE LIMITED**  
Corporate Identity Number: U65900MH2013PTC244758

**Registered Office / Corporate Office:** Unit No. 204, 2<sup>nd</sup> Floor, Amiti Building, Piramal Agastya Corporate Park, LBS Road, Kamani Junction, Kuria (W), Mumbai - 400070.  
Tel: 1800 4196244; website: [www.mahindramanulife.com](http://www.mahindramanulife.com); email id: [mfinvestors@mahindramanulife.com](mailto:mfinvestors@mahindramanulife.com)

**NOTICE NO. 22/2026**

**Declaration of Income Distribution cum Capital Withdrawal ('IDCW') under Mahindra Manulife Aggressive Hybrid Fund**

Notice is hereby given that, in accordance with the Dividend Distribution Policy, as approved by Mahindra Manulife Trustee Private Limited, the Trustee to Mahindra Manulife Mutual Fund ("the Fund"), the Income Distribution cum Capital Withdrawal ("IDCW") has been declared under Monthly IDCW Option(s) of Mahindra Manulife Aggressive Hybrid Fund, an open ended hybrid scheme investing predominantly in equity and equity related instruments ("the Scheme"), as per the details given below:

Plan(s)/Option(s)	Quantum of IDCW # (Rs. per unit)	Record Date*	Face Value (Rs. per unit)	NAV as on June 02, 2026 (Rs. per unit)
Regular Plan - Monthly IDCW Option	0.18	June 08, 2026	10	17.7540
Direct Plan - Monthly IDCW Option	0.18		10	20.6979

\*As reduced by the amount of applicable statutory levy. Distribution of the above IDCW is subject to the availability of distributable surplus and may be lower, depending on the distributable surplus available on the Record Date.

\*If in any case the Record Date falls on a non-business day, the immediately following business day shall be deemed to be the Record Date.

**Pursuant to payment of IDCW, the NAV of the IDCW Option(s) of the Scheme/Plan(s) would fall to the extent of payout and statutory levy, if any.**

All Unit holders / Beneficial Owners under the IDCW Option(s) of the abovementioned Scheme / Plan(s) whose names appear in the records of the Registrar, Computer Age Management Services Ltd. / Statement of Beneficial Owners maintained by the Depositories, as applicable, as at the close of the business hours on the Record Date shall be eligible to receive the IDCW.

With regard to Unit holders under the IDCW Option(s) of the abovementioned Scheme/ Plan(s), who have opted for IDCW Reinvestment facility, the IDCW due will be reinvested by allotting units for the IDCW amount (on the next Business Day after the Record Date) at a price based on the prevailing ex-IDCW NAV per unit on the Record Date.

**For Mahindra Manulife Investment Management Private Limited**  
Sd/  
Authorised Signatory

Place: Mumbai  
Date: June 03, 2026

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.



